Please login to the form below

Not currently logged in
Email:
Password:

Aimmune Therapeutics

This page shows the latest Aimmune Therapeutics news and features for those working in and with pharma, biotech and healthcare.

DBV refiles peanut allergy immunotherapy in the US

DBV refiles peanut allergy immunotherapy in the US

four to 11 years, as it tries to catch up with a rival programme from US company Aimmune Therapeutics that is already under FDA review. ... GlobalData has predicted that Aimmune’s drug will have two-thirds of the market in 2027, with DBV’s drug

Latest news

  • Aimmune wins over ICER for peanut allergy product Aimmune wins over ICER for peanut allergy product

    derailed. Meanwhile, Aimmune also seems to be in the lead in Europe, with a filing due in the next few months. ... GlobalData predicts that Aimmune’s drug will have two thirds of the market in 2027, with DBV’s claiming around a third and other

  • FDA moves into crisis mode as shutdown drags on FDA moves into crisis mode as shutdown drags on

    One company – Aimmune Therapeutics – has already said it has been notified that as a direct result of the shutdown, the FDA will not commence review of its marketing application for peanut

  • Nestlé Health Science invests $145m in food allergy biotech Nestlé Health Science invests $145m in food allergy biotech

    Aimmune Therapeutics' lead product is a phase III peanut allergy treatment.  . ... In addition to its 15% stake in Aimmune Therapeutics, Nestlé has formed a two-year collaboration with the California firm for its immunotherapy research, which is

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Integrating patient reported outcomes into clinical trials Integrating patient reported outcomes into clinical trials

    Aimmune Therapeutics prepared for commercialisation by using two PRO scales to show the effect of its peanut allergy drug on people’s emotions and social lives. ... Cara Therapeutics put two questionnaires about itching at the centre of its phase 3

  • Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019 Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

    Forecast sales for Skyrizi in 2023 are $1.74bn. AR-101 from Aimmune Therapeutics addresses peanut allergy. ... However, Aimmune reported in February 2019 that the FDA had initially determined that the drug, as an allergenic extract, was exempt from the

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Now a US biotech company, Aimmune, looks set to bring the first treatment to market by the end of this year. ... Aimmune Therapeutics submitted the drug to the FDA on 21 December.

  • Deal Watch November 2016 Deal Watch November 2016

    licence, collaboration. 167. Aimmune Therapeutics/ Nestlé Health Science. CODIT (Characterised Oral Desensitisation ImmunoTherapy), for treating life-threatening food. ... acquisition - company. 80. Arsia Therapeutics/ Eagle Pharmaceuticals. viscosity

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

NICE
Evolution or revolution: the latest review of NICE methods
By Leela Barham...
PRO
Integrating patient reported outcomes into clinical trials
How capturing the patient voice is unlocking medicines’ commercial potential...
Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...

Infographics